TY - JOUR
T1 - Superiority Trials in Invasive Aspergillosis
T2 - A Harsh Reality Check With the IA-DUET (HOVON502) Trial
AU - Lamberink, Hanne
AU - Huygens, Sammy
AU - Aerts, Robina
AU - Lagrou, Katrien
AU - van Leeuwen-Segarceanu, Elena
AU - Lodewyck, Tom
AU - Nieuwenhuizen, Laurens
AU - Corsten, Maarten F.
AU - Moors, Ine
AU - Servais, Sophie
AU - De Greef, Julien
AU - Hites, Maya
AU - Demandt, Astrid
AU - Schauwvlieghe, Alexander
AU - Maertens, Johan
AU - Rijnders, Bart
PY - 2024/10/8
Y1 - 2024/10/8
N2 - The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
AB - The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=eur_pure&SrcAuth=WosAPI&KeyUT=WOS:001351011800001&DestLinkType=FullRecord&DestApp=WOS_CPL
U2 - 10.1093/cid/ciae501
DO - 10.1093/cid/ciae501
M3 - Article
C2 - 39378343
SN - 1058-4838
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
M1 - ciae501
ER -